Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer

PURPOSE: Trastuzumab has markedly improved the survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in combination with taxanes (THP) has become a standard of care for HER2-positive metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong-Pyo, Lee, Min-Sang, Kim, HongSik, Kim, Ji-Yeon, Ahn, Jin Seok, Im, Young-Hyuck, Park, Yeon Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582483/
https://www.ncbi.nlm.nih.gov/pubmed/35038825
http://dx.doi.org/10.4143/crt.2021.1103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582483/
https://www.ncbi.nlm.nih.gov/pubmed/35038825
http://dx.doi.org/10.4143/crt.2021.1103

Ejemplares similares